New drug shows promise for painful skin condition
NCT ID NCT04762277
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tested a medicine called spesolimab in 52 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and boils. Participants received either spesolimab or a placebo for about 3 months. Doctors counted skin lesions to see if spesolimab reduced them more than placebo. The goal was to find a new treatment option for this difficult condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Universitaria Pisana
Pisa, 56126, Italy
-
CLI Reims Bezannes
Bezannes, 51430, France
-
Cityclinic Medical and Psychological Clinic Matusiak Partnership
Wroclaw, 50-566, Poland
-
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250, United States
-
Dermatology Research Associates
Los Angeles, California, 90045, United States
-
Dr. S. K. Siddha Medicine Professional Corporation
Newmarket, Ontario, L3Y 5G8, Canada
-
Erasmus Medisch Centrum
Rotterdam, 3015 GD, Netherlands
-
HOP Edouard Herriot
Lyon, 69003, France
-
HOP Larrey
Toulouse, 31059, France
-
Haukeland Universitetssykehus
Bergen, N-5021, Norway
-
Holdsworth House Medical Practice
Sydney, New South Wales, 2010, Australia
-
Hospital Santa Creu i Sant Pau
Barcelona, 08026, Spain
-
Katholisches Klinikum Bochum gGmbH
Bochum, 44791, Germany
-
Mayo Clinic, Rochester
Rochester, Minnesota, 55905, United States
-
Non-Public Health Care Facility LABDERM
Ossy, 42624, Poland
-
Nordlandssykehuset HF, Bodø
Bodø, 8005, Norway
-
Oslo Universitetssykehus HF, Rikshospitalet
Oslo, N-0372, Norway
-
Ospedali Riuniti di Ancona
Ancona, 60123, Italy
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Städtisches Klinikum Dessau
Dessau, 06847, Germany
-
ULB Hopital Erasme
Brussels, 1070, Belgium
-
Unity Clinical Research
Oklahoma City, Oklahoma, 73118, United States
-
University Hospital Ostrava
Ostrava, 708 52, Czechia
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596, Germany
Conditions
Explore the condition pages connected to this study.